Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dopobid
- Development stage
- Unknown
- Lead developer
- Austrak
- Modality
- Small Molecules
- Administration
- Ophthalmic, Oral
01
Overview
Dopobid is a brand name used by Austrak Pharmaceuticals for two distinct pharmaceutical products: an ophthalmic solution and an oral tablet. In the context of ophthalmology, Dopobid refers to a combination eye drop containing **dorzolamide hydrochloride** (a carbonic anhydrase inhibitor) and **timolol maleate** (a non-selective beta-adrenergic receptor blocker). This formulation is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers alone. Additionally, Austrak markets a tablet under the same brand name containing **levodopa** and **carbidopa**, which is used in the management of Parkinson's disease. The ophthalmic version works by decreasing the production and secretion of aqueous humor, while the neurological version works by replenishing dopamine levels in the brain.
- Brand names
- Dopobid
- Other names
- dorzolamide + timolollevodopa + carbidopa
02
Targets
COXDRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)ADRB1 (β1)ADRB2 (β2)CA2 (Carbonic Anhydrase 2)DDC (Aromatic L-amino acid decarboxylase)
Beyond the preview
Go deeper on Dopobid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dopobid.